Active Ingredient(s): Ibalizumab-uiyk
FDA Approved: * March 6, 2018
Category: HIV / AIDS

* This drug may consist of multiple approval dates, manufacturers, or distributors. If applicable, they would be listed below under "NDC Database Records".

Trogarzo Overview

Ibalizumab (trade name Trogarzo) is a non-immunosuppressive humanised monoclonal antibody that binds CD4, the primary receptor for HIV,[2] and inhibits HIV from entering cells.[3] It is a post-attachment inhibitor, blocking HIV from binding to the CCR5 and CXCR4 co-receptors after HIV binds to the CD4 receptor on the surface of a CD4 cell. Post-attachment inhibitors are a sub-class of HIV drugs called entry inhibitors. In a Phase III trial with 48 weeks of foll...

Read more Trogarzo Details
Details May Include Instructions, Side Effects, Interactions, Etc. Drug monograph is from Wikipedia. All text is available under the terms of the GFDL (GNU Free Documentation License). Source:

Recent Trogarzo Forums:

Be the first to start a discussion about this drug.

Possible Dosages for this and Related Drugs:

  • Injection: 150mg/ml
Note: Above list includes dosages for all drugs with the same combination of active ingredients.

NDC Database Records for Trogarzo: (1 result)

Sorted by National Drug Code
  • 62064-122 Trogarzo 150 mg/ml Intravenous Injection, Solution by Theratechnologies Inc.

Other drugs which contain Ibalizumab-uiyk or a similar ingredient: (1 result)